Literature DB >> 16914087

Melanocortin 5 receptor and ocular immunity.

A W Taylor1, N Kitaichi, D Biros.   

Abstract

The nervous system contributes to the mechanisms of ocular immune privilege by the constitutive presence of the immunosuppressive neuropeptide alpha-melanocyte stimulating hormone (alpha-MSH) in the eye. Alpha-MSH through the melanocortin 5 receptor (MC5r) mediates induction of CD4+ regulatory T cells that suppress in an antigen specific manner autoimmune disease. We investigated whether there was a role for MC5r expression in ocular immunity and the natural induction of regulatory T cells that emerged following resolution of experimental autoimmune uveoretinitis (EAU). Unlike wild type mice, EAU in MC5r-/- mice caused severe retinal damage, did mice expressed a not induce the emergence of ocular autoantigen regulatory immunity in the spleen, and the MC5r-/- classical memory immune response when reimmunized with ocular autoantigen. There was expression of MC5r in retinal pigment epithelial cells, in the ganglion cell and neural outer plexiform layers of healthy wild type mice retinas. The recovery of the ocular microenvironment from EAU was not dependent on the expression of MC5r, nor was the recovery dependent on the induction of CD4+ regulatory T cells (Treg cells) in the spleen. However, protection of the retina from the inflammatory damage of EAU and the induction of ocular autoantigen-responsive CD4+ Treg cells in the post EAU spleen requires expression of MC5r.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16914087

Source DB:  PubMed          Journal:  Cell Mol Biol (Noisy-le-grand)        ISSN: 0145-5680            Impact factor:   1.770


  22 in total

1.  Ocular immune privilege in the year 2010: ocular immune privilege and uveitis.

Authors:  Andrew W Taylor; Henry J Kaplan
Journal:  Ocul Immunol Inflamm       Date:  2010-12       Impact factor: 3.070

2.  Tissue-specific production of MicroRNA-155 inhibits melanocortin 5 receptor-dependent suppressor macrophages to promote experimental autoimmune uveitis.

Authors:  Fauziyya Muhammad; Anna Trivett; Dawei Wang; Darren J Lee
Journal:  Eur J Immunol       Date:  2019-06-19       Impact factor: 5.532

Review 3.  Intracellular signaling mechanisms of the melanocortin receptors: current state of the art.

Authors:  Adriana R Rodrigues; Henrique Almeida; Alexandra M Gouveia
Journal:  Cell Mol Life Sci       Date:  2014-12-12       Impact factor: 9.261

4.  Following EAU recovery there is an associated MC5r-dependent APC induction of regulatory immunity in the spleen.

Authors:  Darren J Lee; Andrew W Taylor
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-11-17       Impact factor: 4.799

Review 5.  Negative regulators that mediate ocular immune privilege.

Authors:  Andrew W Taylor; Tat Fong Ng
Journal:  J Leukoc Biol       Date:  2018-02-12       Impact factor: 4.962

6.  Exacerbation of autoimmune uveitis by obesity occurs through the melanocortin 5 receptor.

Authors:  Fauziyya Y Muhammad; Kayleigh Peters; Dawei Wang; Darren J Lee
Journal:  J Leukoc Biol       Date:  2019-07-09       Impact factor: 4.962

Review 7.  Applications of the role of α-MSH in ocular immune privilege.

Authors:  Andrew W Taylor; Darren Lee
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

Review 8.  Role of melanocortin receptors in the regulation of gouty inflammation.

Authors:  Trinidad Montero-Melendez; Hetal B Patel; Mauro Perretti
Journal:  Curr Rheumatol Rep       Date:  2011-04       Impact factor: 4.592

9.  Injection of an alpha-melanocyte stimulating hormone expression plasmid is effective in suppressing experimental autoimmune uveitis.

Authors:  D J Lee; D J Biros; A W Taylor
Journal:  Int Immunopharmacol       Date:  2009-05-06       Impact factor: 4.932

10.  The diminishment of experimental autoimmune encephalomyelitis (EAE) by neuropeptide alpha-melanocyte stimulating hormone (alpha-MSH) therapy.

Authors:  Andrew W Taylor; Nobuyoshi Kitaichi
Journal:  Brain Behav Immun       Date:  2008-01-02       Impact factor: 7.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.